Search Results for “research” – Page 50 – media

Milestone! Symptoms completely disappeared, dual-antibody treatment of autoimmune diseases published in the New England Journal of Medicine

Targeting B cells and plasma cells is a key strategy for treating a variety of autoimmune diseases. In recent years, chimeric antigen receptor T cell (CAR-T) therapy has made some progress in autoimmune diseases, and many patients who received CD19-targeted CAR-T therapy have achieved long-term drug-free remission. However, the long production process of this type of therapy, the need for patients to undergo pretreatment in advance, and the inability to flexibly adjust the dose of CAR-T cells after the start of treatment have limited its widespread application. In addition, for some patients, their disease may be caused by long-lived plasma cells that express B cell maturation antigen (BCMA) but not CD19. Therefore, even after receiving CD19-targeted CAR-T therapy, autoimmune antibodies such as antinuclear antibodies and polymyositis-scleroderma-associated antibodies (PM-Scl) still exist in patients. In view of the limitations of CAR-T therapy in the application of autoimmune diseases, researchers have set their ...
- Source: drugdu
- 86
- September 16, 2024
After CXO, will the United States start to take action against Chinese APIs?

In response to whether the bill is feasible, the FDA once said, “If there is not enough data to calculate which APIs come from China, what proportion and how much impact, no one can guarantee that there will not be fatal drug shortages, and no one is willing to take such responsibility.” Now, the API industry base survey and assessment initiated by the U.S. Department of Commerce is a comprehensive survey of industry data, which means possible variables in the future. According to reports, in July this year, the Bureau of Industry and Security (BIS) of the U.S. Department of Commerce officially announced that it would cooperate with the Strategic Preparedness and Response Administration (ASPR) under the U.S. Department of Health and Human Services (HHS) to conduct a comprehensive investigation and assessment of the U.S. active pharmaceutical ingredients, or API industry base. The survey aims to understand the supply chain ...
- Source: drugdu
- 53
- September 16, 2024
The light of domestic production! Kangnuo’s IL-4R α antibody drug has been approved for market by NMPA

On September 12th, Konya announced that the company’s independently developed Class 1 new drug, Kangyueda ® (Sipuximab Injection) has been officially approved for marketing by the National Medical Products Administration for the treatment of moderate to severe atopic dermatitis in adults. As the first domestic and second globally approved IL-4R alpha antibody drug, Kangyueda ® The launch of Sipuqibai monoclonal antibody not only fills the gap in the field of domestic atopic dermatitis biologics, but also brings new hope for patients with moderate to severe atopic dermatitis to achieve higher treatment goals. Kangyueda ® (Sprucubizumab) Kangyueda ® The Phase III clinical trial of (Sipuximab) is the largest randomized controlled trial of dermatological subjects completed in China to date. The research results show that, The first dose takes effect quickly: Kangyueda ® The first dose of single agent treatment with (Sipuximab) can quickly relieve itching symptoms within one day; After 2 ...
- Source: drugdu
- 92
- September 14, 2024
Johnson&Johnson increases investment in medical imaging

Recently, medical imaging company Spectra has completed its Series B financing and raised $50 million (approximately RMB 356 million) in funding. It is understood that the funds raised in this round of financing will support the commercial expansion and product increase of Spectra ‘Hypervue imaging system to benefit patients with coronary artery disease. It is worth noting that this round of financing is led by Johnson and Johnson Innovation and supported by investors such as S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture, and Heartwork Capital. Spectrawave， The intravascular imaging system has been approved by the FDA According to publicly available information, Spectra was founded in 2017 and is located in Massachusetts, USA. It is a medical imaging company focused on improving the treatment and prognosis of patients with coronary artery disease (CAD). The Spectral Medical Imaging Platform is the most advanced integration of mature imaging technologies, designed ...
- Source: drugdu
- 69
- September 14, 2024
Baird Medical’ successfully went public in the United States

Recently, Baird Medical’s business merger with overseas special purpose acquisition company ExcelFin Acquisition Corp. has been approved by the US SEC, and the F-4 application documents have officially come into effect, with a declaration of registration effectiveness issued. Baird Medicalhas achieved listing on the NASDAQ Stock Exchange in the United States through the merger with ExcelFin Acquisition Corp., a foreign special purpose acquisition company. In addition, Baird Medicalalso announced that ExcelFin has arranged a special shareholders’ meeting to be held on September 26, 2024. After the meeting, it is expected to receive approval from ExcelFin shareholders and the merger will be completed soon. The bumpy road falls on the eve of going public Before going public in the United States, Baird Medicalhad a bumpy road to going public in Hong Kong. Founded in 2012, Baird Medicalis a leading developer and provider of microwave ablation medical devices for minimally invasive treatment ...
- Source: drugdu
- 61
- September 14, 2024
Increasing Investment in R&D Innovation to Deepen Product Competitive Moats

CSPC Pharmaceutical Group has achieved significant milestones in research and development, securing conditional approval for its self-developed Class 1 new drug, Enlansub, and for the injectable version of Rayzoprazole. The company has also received approval for clinical trials in the U.S. for its antibody-drug conjugate, clinical trial approval for its mRNA vaccine against respiratory syncytial virus, and clinical trial approval for the first CAR-T cell injection based on mRNA-LNP technology. As an innovation-driven enterprise and a key player in the national industrial chain, CSPC continues to enhance its R&D investments, elevate its international influence, and fortify its product competitive edge. This year, various in-development drugs have reached key progress points, with some approved for market launch or clinical trials both domestically and internationally. Currently, CSPC is conducting over 130 innovative drug projects, with more than 50 new drugs expected to be launched in the next five years. Comprehensive Market Coverage ...
- Source: drugdu
- 76
- September 14, 2024
Another new COPD drug is coming

On September 6, GlaxoSmithKline (GSK) announced that its Phase 3 MATINEE study of its IL-5 antibody Nucala (mepolizumab) in the treatment of COPD achieved positive results. Compared with the placebo group, the Nucala treatment group achieved a statistically significant reduction in the annualized rate of moderate to severe exacerbations, but specific data have not yet been released. Two months ago, two COPD drugs with new mechanisms: ensifentrine and dupilumab were approved for marketing in the United States and Europe, refreshing the treatment model of this severe respiratory disease. Mepolizumab is expected to join this new round of competition. COPD: The third leading cause of death in humans Chronic obstructive pulmonary disease (COPD), referred to as COPD, is a common, preventable and treatable heterogeneous disease. According to statistics from the World Health Organization, COPD has become the third leading cause of death in humans, with about 11% of people dying from ...
- Source: drugdu
- 68
- September 14, 2024
Ascentage Pharma’s “Nerlik®” received an oral presentation

Ascentage Pharma (6855.HK) announced today that the company has published the clinical research results of the company’s original Class 1 new drug Olebatinib (trade name: Nerlik®; research and development code: HQP1351) for the treatment of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST) in the form of a mini oral presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting. The clinical data of this oral presentation showed that Olebatinib has sustained clinical efficacy in the treatment of SDH-deficient GIST. As of March 12, 2024, 6 of the 26 patients with SDH-deficient GIST enrolled achieved partial remission (PR), the objective response rate (ORR) was 23.1%, and the median progression-free survival (PFS) was 22 months. In addition, potential mechanism of action (MOA) studies have shown that orebactinib exerts anti-tumor activity by regulating multiple signaling pathways involved in angiogenesis, apoptosis, proliferation and survival. Orebactinib is an original Class 1 new drug ...
- Source: drugdu
- 67
- September 14, 2024
Traditional Chinese Medicine Brands Accelerate Penetration into Young Consumer Groups

In recent years, health-oriented and personalized dietary trends, exemplified by new-style tea beverages, have rapidly gained popularity among young consumers. Building on this foundation, with an increasing awareness of health and wellness, traditional Chinese medicine (TCM) health drinks, with their unique health philosophies and rich cultural backgrounds, have gradually won recognition among younger demographics. Reports from the China Securities Journal indicate that it’s not just beverage products; under consumer demand, renowned TCM brands such as Tong Han Chun Tang, Tong Ren Tang, Lei Yun Shang, and Hu Qing Yu Tang are actively launching new products featuring TCM ingredients, including medicinal dishes, herbal scents, and skincare items, tailored to meet the genuine needs of younger consumers. Experts believe that as these brands expand their product lines and target consumption scenarios, it will help rejuvenate the long-standing TCM brands. Targeting Youth to Enhance Product Offerings Historically, traditional TCM shops have not been ...
- Source: drugdu
- 103
- September 13, 2024
Focusing on the Frontiers of Biomedicine and Creating an Open Source Innovation Ecosystem.

Recently, a reporter from China Securities Journal visited the Shanghai Frontier Biomedical Innovation Center. Driving into the core area of the Zhangjiang Science City, a national-level biomedical base, one can see a modern, curved building from afar. Approaching closer, the open interior, visible through the yellow and white glass, creates a sense of freedom and positivity. “Currently, 10 resident companies and 11 ecological partners have signed cooperation agreements with Shanghai Frontier,” a representative from Shanghai Frontier stated. The center aims to create a “wall-less R&D center,” breaking down traditional barriers and promoting interaction and collaboration among experts, scholars, businesses, and investors from various fields and backgrounds, including industry, education, research, healthcare, and finance. Looking ahead, Shanghai Frontier will focus on cutting-edge biotechnologies such as gene and cell therapy, nucleic acid drugs, and conjugated drugs, hoping to discover and nurture highly innovative and competitive companies and projects while encouraging high-potential innovations ...
- Source: drugdu
- 113
- September 13, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.